Laboratory studies will develop methods to examine the reinforcing and discriminative effects of alcohol, caffeine and nicotine in humans, examine the effects of nicotine administration in smokers and nonsmokers, further characterize caffeine and nicotine withdrawal, describe the effects of combining stimulants (e.g. cocaine) and sedatives (e.g. alcohol) and test the effects of drugs on learning, performance and social interaction. Laboratory studies will also examine the influence of environmental, pharmacological, organismic (e.g. behavioral history and genetics) and procedural variables on the reinforcing, discriminative, and direct effects of drugs. Epidemiological studies will longitudinally study the process of smoking cessation in self-quitters, examine the prevalence of DSM-III-R defined caffeine and nicotine disorders, and test the association of nicotine dependence with past and present psychiatric disorders. Treatment studies will test new nicotine replacement and non-nicotine pharmacological treatments for nicotine dependence, as well as behavioral treatments for cocaine and nicotine dependence. Continued funding of the candidate will help develop the Human Behavioral Pharmacology Laboratory and allow the applicant to select only administrative, clinical and teaching activities that are consistent with his career goals and growth of the laboratory.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Development Award - Research (K02)
Project #
5K02DA000109-10
Application #
2115923
Study Section
Special Emphasis Panel (SRCD (41))
Project Start
1985-09-30
Project End
1995-08-31
Budget Start
1994-09-01
Budget End
1995-08-31
Support Year
10
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Vermont & St Agric College
Department
Psychiatry
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
05405
Kamien, J B; Bickel, W K; Smith, B J et al. (1997) Secobarbital in humans discriminating triazolam under two-response and novel-response procedures. Pharmacol Biochem Behav 58:983-91
Hughes, J R (1996) The future of smoking cessation therapy in the United States. Addiction 91:1797-802
Fagerstrom, K O; Kunze, M; Schoberberger, R et al. (1996) Nicotine dependence versus smoking prevalence: comparisons among countries and categories of smokers. Tob Control 5:52-6
Hughes, J R; Higgins, S T; Bickel, W K (1994) Common errors in the pharmacologic treatment of drug dependence and withdrawal. Compr Ther 20:89-94
Hughes, J R (1993) Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol 61:751-60